Efficacy and Safety of Symbravo® in Participants with Migraine Experiencing an Inadequate Response to Oral CGRP Inhibitors
Dr. Bradley Ong shares early insights from the EMERGE trial, presented at the American Headache Society's 67th Annual Scientific Meeting in June 2025. Show reference
Read the full articleYou might also wanna read
Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Prevention of Migraine in the United Kingdom
Conditions : Migraine Sponsors : AbbVie Not yet recruiting
Intranasal Zavegepant for the acute treatment of migraine in adults: A review of randomized clinical trials
Migraine is a highly prevalent chronic neurological disorder and one of the leading causes of disability worldwide. Among recent therapeutic
CGRP monoclonal antibody fremanezumab may reduce weather-triggered migraine attacks, study finds
Preventive treatment may blunt the impact of weather-related migraine triggers, in what investigators say is a first for migraine prevention
mdsc.pe·21d ago
Real-world study suggests GLP-1 receptor agonists may reduce emergency visits and medication needs for chronic migraine
Real-world data suggest GLP-1 receptor agonists may reduce emergency care visits and the need for additional migraine treatments in adults w
mdsc.pe·6d ago
CME | This Is Giving Me a Headache: Managing the Headache Patient Without Losing Your Mind
In this re-released episode of CME on the Go, originally published on 12/1/2025, our hosts discuss the complexities of diagnosing and treati
Pharmaceutical Method-of-Use Claims After Teva v. Eli Lilly and In re Xencor: Written Description, Enablement, and the Known-Compound Genus
Introduction Two recent Federal Circuit decisions offer complementary guidance on a recurring question in patent law: what must a patent spe
Comments
Sign in to join the conversation.
No comments yet. Be the first.